Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00462787 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00462787: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00462787 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00462787, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as clofarabine, topotecan, vinorelbine, thiotepa, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of clofarabine when given together with topotecan, vinorelbine, thiotepa, and dexamethasone in treating young patients with relapsed or refractory acute leukemia.
Interventions
- DRUG dexamethasone
- DRUG clofarabine
- BIOLOGICAL filgrastim
- DRUG thiotepa
- DRUG topotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2007-04 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00462787
The ClinicalTrials.gov registry entry for NCT00462787 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which dexamethasone is the first listed.
NCT00462787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00462787 about?
NCT00462787 is a clinical study titled "Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia". RATIONALE: Drugs used in chemotherapy, such as clofarabine, topotecan, vinorelbine, thiotepa, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill mor...
What is the current status of trial NCT00462787?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2007-04. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00462787?
The interventions under investigation include: dexamethasone (DRUG), clofarabine (DRUG), filgrastim (BIOLOGICAL), thiotepa (DRUG), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00462787?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.